Study Links GLP-1 Drugs to 30% Lower Breast Cancer Risk in 111,646 Women
Updated
Updated · springermedicine.com · Jun 19
Study Links GLP-1 Drugs to 30% Lower Breast Cancer Risk in 111,646 Women
3 articles · Updated · springermedicine.com · Jun 19
Summary
Breast cancer occurred in 1.62% of GLP-1 users versus 2.31% of nonusers in a matched analysis of 15,264 pairs, an absolute risk reduction of 0.69 percentage points.
The observational study drew on electronic health records for 111,646 U.S. women aged 45 to 80 with BMI of at least 25 who underwent breast imaging from January 2022 to June 2025.
Propensity-score matching adjusted for age, race and ethnicity, BMI, breast density and type 2 diabetes status, and the unmatched analysis also showed significantly lower cancer incidence among GLP-1 users.
Elizabeth McDonald told ASCO the findings are hypothesis-generating rather than causal because residual confounding and incomplete prescription capture remain possible.
Researchers said the signal adds to evidence of benefits beyond weight loss and glycemic control, and they plan to launch a large randomized prevention trial within months.
Could a pill for cancer prevention make us ignore the root causes of obesity?
Is weight loss the real hero, or do these drugs have a secret cancer-fighting power?
GLP-1 Drugs and Breast Cancer: New Evidence from ASCO 2026 Points to Prevention Potential
Overview
At the 2026 ASCO Annual Meeting, Dr. Elizabeth McDonald presented new findings showing that GLP-1 medications—originally developed for diabetes and now widely used for obesity—may help reduce breast cancer risk. Her team’s goal is to improve breast cancer prevention, building on past progress in survival rates. The research sparked major discussion among experts, as GLP-1 drugs work by changing hormonal balance in the brain and gut. While these early results are promising, more research is needed to confirm if GLP-1s can truly prevent breast cancer and to understand how they work in the body.